Please login to the form below
Tysabri
This page shows the latest Tysabri news and features for those working in and with pharma, biotech and healthcare.
Biogen to pay $900m to settle whistleblower’s MS drug kickback lawsuit
This was done to encourage HCPs to prescribe the MS drugs Avonex (interferon-beta-1a), Tysabri (natalizumab) and Tecfidera (dimethyl fumarate), in violation of the Anti-Kickback Statute, it was alleged.
Latest news
-
Sandoz’s application for MS biosimilar accepted by FDA
The proposed ‘first-of-a-kind’ biosimilar matched the reference medicine, Biogen’s Tysabri, in terms of efficacy, safety and immunogenicity. ... Each study met its primary endpoints, demonstrating that the biosimilar matches the reference medicine,
-
Biogen pays InnoCare $125m upfront for potential multiple sclerosis treatment
Orelabrutinib will fit neatly into Biogen’s MS portfolio, which includes Tecfidera (dimethyl fumarate), Tysabri (natalizumab) and Vumerity (diroximel fumarate).
-
Biogen reveals new data for MS therapies Tysabri and Vumerity
The adjusted annualised rate of improvement was greater with Tysabri treatment compared with Ocrevus in 11 of 12 domains on the Neuro-QoL questionnaire. ... In addition to the Tysabri data, Biogen also disclosed findings on the use of Vumerity (diroximel
-
Novartis expands its generics franchise with natalizumab biosimilar
Says affordability is a challenge to access. Sandoz, Novartis’ generics unit, has agreed to license a biosimilar of Biogen’s Tysabri for multiple sclerosis from Polpharma Biologics. ... The biosimilar franchise in Europe has grown in recent years,
-
Biogen grows in Q2, but Spinraza performance a concern
The performance was thanks largely to its under-pressure multiple sclerosis (MS) franchise, where combined sales of Tecfidera, Avonex, Plegridy and Tysabri totalled $2.2bn.
More from news
Approximately 6 fully matching, plus 96 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2017
The largest of these was Perrigo's divestment to Royalty Pharma of its royalty stream from Biogen's global sales of Tysabri (natalizumab), the multiple sclerosis antibody originally developed by Elan, ... 17, 900. Perrigo/ Royalty Pharma. Tysabri
-
Deal Watch table for July 2013
Elan / Perrigo. Acquisition. Tysabri royalty stream, R&D programmes/ EU HQ &operations.
-
Pharma deals during July 2013
In addition to this is the very attractive tiered double digit royalty stream from Tysabri. ... Sales of Tysabri in 2012 were $1.6bn. Acquisitions - a route to bolstering a core business.
-
Pharma deals during May 2013
The Elan/ Royalty Pharma saga began following Biogen Idec's decision in February to buy out the Tysabri rights from Elan for $3.25bn. ... Following the close of the Tysabri deal in early April, Elan went on a spending spree in May.
-
Pharma deals during February 2013
Deal of the month. The largest agreed deal announced was Biogen Idec's acquisition of Elan's interest in Tysabri (natalizumab), the multiple sclerosis (MS) treatment, thereby terminating their previous collaboration ... Tysabri's sales amounted to $1.6bn
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Voyager Therapeutics appoints Matthew Ottmer as chief operating officer
Prior to Momenta, Ottmer spent 16 years at Biogen in a variety of leadership roles including senior vice president, strategy and emerging businesses, head of Tysabri business, chief of staff to
-
Michael Fleming joins biosimilars firm Coherus
Fleming was most recently at Elan where he was head of commercial and of the company's Tysabri (natalizumab) franchise. ... Fleming gained experience in commercialising biological medicines during his time leading the strategy for Elan's multiple
-
XenoPort appoints chief medical officer
Richard Kim led Tysabri programme at Biogen Idec. XenoPort has appointed Dr Richard Kim as chief medical officer and senior VP, clinical development and medical affairs. ... He joined XenoPort from Biogen Idec where he was joint programme team leader for
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Covid-19: how is it affecting prescribing patterns?
Between May 2019 and May 2020, there was a reduction in several key treatments: Lemtrada, Tysabri and Gilenya. ... Lemtrada is a monoclonal antibody (MAB) given by infusion. Tysabri, or natalizumab, is also an infusion injection.
-
It's time to change the conversation
connections. While promotional spend on their drug Tysabri at launch was focused on specialist detailing and medical events, the promotional mix has evolved with increased direct to consumer spend and direct
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- MHRA to introduce new UK clinical trials framework
- Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches
- 2023 PM Society Awards – winners announced
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- WHO report highlights impact of COVID-19 pandemic on non-communicable diseases
- Critical success factors and the increasing value of rare disease clinical trials
- Quantum Computing, Artificial Intelligence, & Machine Learning for Drug Discovery
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Pfizer pays Royalty Pharma $475m following US approval of migraine nasal spray
- Biogen and Eisai’s Alzheimer’s drug to be covered by US Veterans Health Administration
- VR/AR Applications for Training and Healthcare
PMHub
Collected Group
Collected Group is a forward thinking healthcare communication company that supports biopharma and diagnostic companies to engage in more lasting...
Latest intelligence
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
- Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
- Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
- DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
- It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...
